ANNEX B NATIONAL MAS AUTHORISED VIA MRPDCP MRPDCP NO

17 ANNEX II QUOTA FREE REGIME FOR
2 ANNEX 1 CANCELLED PLANTING PROPOSALS AND
2 F ANNEXURE IV INANCIAL BID

3 ANNEX 2 ITUD REGIONAL DEVELOPMENT FORUMS
5 ANNEX C THE SECRETARIAT FOR POLITICAL
9 7D129 (ANNEX 3)E RADIOCOMMUNICATION STUDY GROUPS

Annex B_worksharing


Annex B


National MAs authorised via MRP/DCP


MRP/DCP no. 1

Member State EU/EEA2

National MA number

Marketing Authorisation Holder3

(Invented) name4

Active substance(s)

Strength(s)5

Pharmaceutical Form6

<Content

(concentration)>7




























































































Purely-national MAs


Member State EU/EEA8

National MA number

National variation no. 9

Marketing Authorisation Holder10

(Invented) name11

Active substance(s)

Strength(s) 12

Pharmaceutical Form13

<Content

(concentration)>14




























































































1 MRP/DCP no. of initial marketing authorisation

2 List all the EEA Countries where the medicinal product(s) included in the worksharing are authorised, grouped by MRP/DCP no., with countries in alphabetical order (i.e. all medicinal products authorised in Austria, followed by all medicinal products authorised in Belgium, etc.)

3 Name and address of the Marketing Authorisation Holder in the EEA Countries where the medicinal product is authorised

4 As registered in the respective official language of the EEA Country (no strength or pharmaceutical form should be mentioned unless it is an integral part of the authorised (invented) name)

5 It is possible to combine in the same row several strengths for the medicinal product in each Country. A separate row should however be used for each pharmaceutical form.

6 Information in English - use current standard terms from the Ph. Eur.

7 Complete only if applicable (only for liquids, creams and solid multidose forms, e.g. granules, powder, etc – not for tablets and capsules)

8 List all the EEA Countries where the medicinal product(s) included in the worksharing are authorised, in alphabetical order (i.e. all medicinal products authorised in Austria, followed by all medicinal products authorised in Belgium, etc.)

9 If applicable

10 Name and address of the Marketing Authorisation Holder in the EEA Countries where the medicinal product is authorised

11 As registered in the respective official language of the EEA Country (no strength or pharmaceutical form should be mentioned unless it is an integral part of the authorised (invented) name)

12 It is possible to combine in the same row several strengths for the medicinal product in each Country. A separate row should however be used for each pharmaceutical form.

13 Information in English - use current standard terms from the Ph. Eur.

14 Complete only if applicable (only for liquids, creams and solid multidose forms, e.g. granules, powder, etc – not for tablets and capsules)



ANNEX B2 PRODUCT ENVIRONMENTAL ATTRIBUTES COMPUTERS AND
ANNEX NO 1 TITLE NAME AND SURNAME OF
 COMUNICAT DE PREMSA  ANNEX DESCRIPCIÓ DELS


Tags: mrpdcp, annex, authorised, national